Crimean-congo hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice

Vector-Borne and Zoonotic Diseases

Volumn 15, Issue 12, 2015, Pages 759-764

  Kortekaas, Jeroen ^a   Vloet, Rianka P M ^a   Mcauley, Alexander J ^b,c   Shen, Xiaoli ^b,c   Bosch, Berend Jan ^d   De Vries, Laura ^d   Moormann, Rob J M ^a,d   Bente, Dennis A ^b,c  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b University of Texas Medical Branch School of Medicine   (United States)

^c Galveston National Laboratory   (United States)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Bunyavirus; Crimean Congo hemorrhagic fever virus; Gc; Gn; Nairovirus; Neutralizing antibodies; STAT1; STAT129; Vaccine

Indexed keywords

GLYCOPROTEIN GC; GLYCOPROTEIN GN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; STAT1 PROTEIN; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; GLYCOPROTEIN; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; DRUG EFFICACY; DRUG SOLUBILITY; DRUG TREATMENT FAILURE; EXPERIMENTAL DROSOPHILA; FEMALE; GENE EXPRESSION SYSTEM; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SINGLE DRUG DOSE; VACCINATION; VACCINE PRODUCTION; VIRUS NEUTRALIZATION; ANIMAL; CHEMISTRY; DISEASE MODEL; DROSOPHILA; GENETICS; HEMORRHAGIC FEVER, CRIMEAN; HUMAN; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; NAIROVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; DISEASE MODELS, ANIMAL; DROSOPHILA; FEMALE; GLYCOPROTEINS; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MICE; MICE, KNOCKOUT; STAT1 TRANSCRIPTION FACTOR; VACCINATION; VACCINES, SUBUNIT; VIRAL VACCINES;

EID: 84951858922     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2015.1855     Document Type: Article

References (19)

1. Bente DA, Alimonti JB, Shieh WJ, Camus G., et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010; 84: 11089-11100.
2. Bente DA, Forrester NL, Watts DM, McAuley AJ., et al. Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res 2013; 100:159-189.
3. Bereczky S, Lindegren G, Karlberg H, Akerstrom S., et al. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. J Gen Virol 2010; 91:1473-1477.
4. Bertolotti-Ciarlet A, Smith J, Strecker K, Paragas J., et al. Cellular localization and antigenic characterization of Crimean-Congo hemorrhagic fever virus glycoproteins. J Virol 2005; 79:6152-6161.
5. Bowick GC,AiroAM, Bente DA. Expression of interferon-induced antiviral genes is delayed in a STAT1 knockout mouse model of Crimean-Congo hemorrhagic fever. Virol J 2012; 9:122.
6. Brown KS, Safronetz D, Marzi A, Ebihara H., et al. Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus. J Virol 2011; 85:12781-12791.
7. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A., et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. PLoS One 2014; 9:e91516.
8. Christova I, Kovacheva O, Georgieva G, Ivanova S., et al. Vaccine against Crimean-Congo haemorrhagic fever virus-Bulgarian input in fighting the disease. Problems of Infectious Parasitic Diseases 2010; 37:7-8.
9. de Boer SM, Kortekaas J, Antonis AF, Kant J., et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010; 28:2330-2339.
10. Franceschi V, Parker S, Jacca S, Crump RW., et al. BoHV-4-based vector single heterologous antigen delivery protects STAT1(-/-) mice from monkeypoxvirus lethal challenge. PLoS Negl Trop Dis 2015; 9:e0003850.
11. Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. Clin Vaccine Immunol 2011; 18:2031-2037.
12. Pekosz A, Griot C, Stillmock K, Nathanson N., et al. Protection from La Crosse virus encephalitis with recombinant glycoproteins: Role of neutralizing anti-G1 antibodies. J Virol 1995; 69:3475-3481.
13. Raymond J, Bradfute S, Bray M. Filovirus infection of STAT-1 knockout mice. J Infect Dis 2011; 204(Suppl 3):S986-S990.
14. Sanchez AJ, Vincent MJ, Erickson BR, Nichol ST. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 28-kilodalton glycoprotein. J Virol 2006; 80:514-525.
15. Spik K, Shurtleff A, McElroy AK, Guttieri MC., et al. Immunogenicity of combinationDNAvaccines forRiftValley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006; 24:4657-4666.
16. Tkachenko EA, Butenko AM, Butenko SA, Zaradova TI., et al. Prophylactic characteristics of a protective Crimean hemorrhagic fever vaccine. In: Chumakov MP, ed. Crimean Hemorrhagic Fever-Materials of the 3rd Scientific-Practical Conference in Rostov-na-Donu Region. USSR, Moscow, 1970:136-138.
17. Viral Hemorrhagic Fevers. Moscow, USSR: Trudi Instituta Poliomielita i Virusnykh Entsefalitov, USSR Adademy of Medical Sciences, 1971:119-129.
18. Vancott JL, McNeal MM, Choi AH, Ward RL. The role of interferons in rotavirus infections and protection. J Interferon Cytokine Res 2003; 23:163-170.
19. Zivcec M, Safronetz D, Scott D, Robertson S., et al. Lethal Crimean-Congo hemorrhagic fever virus infection in interferon alpha/beta receptor knockout mice is associated with high viral loads, proinflammatory responses, and coagulopathy. J Infect Dis 2013; 207:1909-1921.